Clinical trials
Phase 2 Lung Neoplasms trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 30 |
| Unknown status | 16 |
| Recruiting | 5 |
| Terminated | 5 |
| Active, not recruiting | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Center, Korea | 9 |
| Yonsei University | 6 |
| AstraZeneca | 5 |
| Novartis Pharmaceuticals | 4 |
| Pfizer | 4 |
| Samsung Medical Center | 4 |
| Boehringer Ingelheim | 3 |
| Chonnam National University Hospital | 3 |
| Arcus Biosciences, Inc. | 2 |
| Incyte Corporation | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 60 |
| Carcinoma, Non-Small-Cell Lung | 36 |
| Adenocarcinoma of Lung | 7 |
| Neoplasm Metastasis | 6 |
| Neoplasms | 5 |
| Pancreatic Neoplasms | 4 |
| Small Cell Lung Carcinoma | 4 |
| Urinary Bladder Neoplasms | 4 |
| Adenocarcinoma, Bronchiolo-Alveolar | 3 |
| Biliary Tract Neoplasms | 2 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.